Related Experiment Videos
Development of an interleukin-2 slow delivery system
J Matsuoka1, K Sakagami, S Shiozaki
1Department of Surgery, Okayama University Medical School, Japan.
ASAIO Transactions
|July 1, 1988
Summary
Researchers created a novel slow-release drug delivery system using bovine collagen for interleukin-2 (IL-2). This collagen-based system effectively prolongs IL-2 retention and reduces side effects, showing promise for other medications.
Area of Science:
- Biomaterials Science
- Pharmacology
- Drug Delivery Systems
Background:
- Interleukin-2 (IL-2) is crucial for immune responses but suffers from rapid clearance and significant side effects.
- Conventional IL-2 administration methods lead to short serum half-lives and potential toxicity.
- Developing sustained-release formulations is essential to improve IL-2 therapeutic efficacy and safety.
Purpose of the Study:
- To develop a novel slow delivery system for interleukin-2 (IL-2) using highly purified bovine collagen.
- To evaluate the pharmacokinetic profile and safety of IL-2 delivered via collagen mini-pellets.
- To assess the potential applicability of this collagen-based drug delivery system for other therapeutic agents.
Main Methods:
- Recombinant human IL-2 was infused into needle-shaped "IL-2 mini-pellets" composed of highly purified bovine collagen.
- Pharmacokinetic studies were conducted in C57BL/6 mice following subcutaneous injection of IL-2 mini-pellets.
- Serum concentrations and elimination half-lives of IL-2 were compared between mini-pellets and aqueous IL-2 injections (intravenous and subcutaneous).
Main Results:
- A single subcutaneous injection of IL-2 mini-pellets successfully prolonged IL-2 retention in C57BL/6 mice.
- The maximal serum concentration of IL-2 was decreased with the mini-pellet formulation.
- The elimination half-life of IL-2 was significantly extended to 360 minutes with subcutaneous mini-pellets, compared to 8 and 15 minutes for intravenous and subcutaneous aqueous IL-2, respectively.
- No adverse side effects were observed during the experimental period.
Conclusions:
- Bovine collagen serves as an effective carrier for developing a slow delivery system for IL-2.
- The IL-2 mini-pellet formulation demonstrates improved pharmacokinetics, including prolonged retention and reduced peak serum concentration.
- This collagen-based slow delivery system is a promising approach for enhancing drug efficacy and safety, with potential applications for various therapeutic agents.